의약품 부형제 시장 : 규모, 점유율, 성장, 산업 분석, 지역 인사이트 및 예측(2026-2034년)

Growth Factors of pharmaceutical excipients Market

The global pharmaceutical excipients market was valued at USD 10.57 billion in 2025 and is projected to grow from USD 11.18 billion in 2026 to USD 17.89 billion by 2034, registering a CAGR of 6.06% during the forecast period. Pharmaceutical excipients are inactive ingredients used in drug formulations to improve stability, solubility, taste, texture, bioavailability, and manufacturing performance. They play an important role in tablets, capsules, injectables, topical products, respiratory drugs, ophthalmic products, and advanced drug delivery systems.

Market growth is mainly driven by rising generic drug production, increasing demand for complex formulations, growing biopharmaceutical development, and higher need for functional and high-purity excipients. North America dominated the market in 2025 with a 27.34% market share, supported by a mature pharmaceutical manufacturing base and strong demand for quality drug formulations.

Pharmaceutical Excipients Market Trends

A major trend in the market is the rising demand for multifunctional excipients. Pharmaceutical companies increasingly prefer excipients that can perform multiple roles, such as improving solubility, stability, release control, taste masking, and manufacturing efficiency. This helps reduce formulation complexity and shorten development timelines.

In September 2024, Evonik started operations at a new spray-drying facility for EUDRAGIT polymers in Darmstadt to meet growing demand for oral drug delivery solutions.

Market Drivers

The key driver of the pharmaceutical excipients market is the rising production of generic drugs. Generic manufacturers require large volumes of fillers, binders, coatings, stabilizers, disintegrants, and solubilizers to develop cost-effective formulations. As more branded drugs lose patent protection, generic drug manufacturing is expanding, directly increasing demand for excipients.

In addition, rising development of specialty therapies, biologics, and advanced dosage forms is increasing the need for high-performance excipients that support drug stability, delivery, and patient compliance.

Market Restraints

High quality-control and supplier-qualification requirements are restraining market growth. Since excipients directly affect drug safety and performance, pharmaceutical companies must conduct strict supplier audits, contamination checks, documentation reviews, and repeated quality testing. These processes increase procurement time, operating costs, and formulation complexity, slowing faster market adoption.

Market Opportunities

The growing demand across oral, respiratory, ophthalmic, parenteral, and topical dosage forms is creating strong opportunities. Drug manufacturers are expanding beyond traditional tablets and capsules into inhalation therapies, sterile injectables, eye care drugs, and advanced delivery systems. This increases demand for excipients with specific purity, safety, and performance characteristics.

In January 2025, DFE Pharma expanded its Closer to the Formulator Center of Excellence in Hyderabad to support respiratory formulation development.

Market Challenges

Strict regulatory requirements and complex approval processes remain major challenges. New excipients require strong safety data, compliance documentation, GMP standards, and region-specific approvals. Lack of global regulatory harmonization can delay excipient innovation and increase development costs, especially for novel and advanced excipient systems.

Segment Analysis

By type, the market is divided into organic and inorganic excipients. The organic segment dominated in 2025 due to wide use of cellulose derivatives, povidones, copovidones, cyclodextrins, and organic solubilizers in tablets, capsules, liquids, and controlled-release formulations. The inorganic segment is projected to grow at a CAGR of 6.81%.

By formulation, the oral solid dosage segment dominated in 2025. Tablets and capsules remain the most widely used and cost-efficient dosage forms, requiring large excipient volumes for filling, binding, coating, disintegration, and release control. The parenteral segment is expected to grow at a CAGR of 8.43%.

By functionality, primary processing and performance roles led the market in 2025. These include filling, binding, lubrication, flow support, compression support, and disintegration, which are essential in large-scale pharmaceutical manufacturing. Device-compatibility roles are expected to grow at a CAGR of 8.88%.

By functionality application, immediate-release and content uniformity enablement held the largest share due to high demand for uniform API distribution and reliable tablet manufacturing. Solubility and bioavailability enhancement is projected to grow at a CAGR of 7.57%.

By source, plant-derived excipients dominated the market due to their wide availability, regulatory familiarity, and use in tablets, capsules, and patient-friendly formulations. Mineral-derived excipients are expected to grow at a CAGR of 6.89%.

By end user, pharmaceutical and biopharmaceutical companies dominated in 2025, as they are the largest consumers of excipients across formulation development, scale-up, regulatory filing, and commercial production. CMOs/CDMOs are projected to grow at a CAGR of 8.31%.

Regional Analysis

North America led the market with USD 2.89 billion in 2025, increasing from USD 2.75 billion in 2024. The U.S. market is estimated at USD 2.79 billion in 2026, representing around 25.01% of global revenue.

Europe is projected to reach USD 2.67 billion in 2026, growing at 5.02%. The U.K. market is estimated at USD 0.51 billion, while Germany is expected to reach USD 0.61 billion in 2026.

Asia Pacific is estimated to reach USD 3.84 billion in 2026, driven by expanding generic drug production in India and China. China is projected at USD 1.26 billion, Japan at USD 0.87 billion, and India at USD 0.51 billion in 2026.

Latin America is expected to reach USD 0.90 billion in 2026, while the GCC market is projected at USD 0.35 billion.

Competitive Landscape

Key players include Roquette Freres, BASF Pharma Solutions, Evonik Industries AG, Ashland Inc., Croda Pharma, MEGGLE Excipients, SPI Pharma, JRS Pharma, Shin-Etsu Chemical, and Colorcon Limited. These companies focus on product launches, partnerships, GMP facility expansion, and advanced excipient technologies.

Conclusion

The pharmaceutical excipients market is expected to grow from USD 10.57 billion in 2025 to USD 11.18 billion in 2026, reaching USD 17.89 billion by 2034. Growth will be supported by generic drug expansion, advanced formulations, biopharmaceutical development, and increasing demand for multifunctional excipients. Despite regulatory and quality-control challenges, innovation in high-performance excipients will continue to drive market growth.

Segmentation By Type, Formulation, Functionality, Functionality Application, Source, End User, and Region

By Type * Organic Chemicals

• Carbohydrates & Derivatives
• Polymers
• Lipids, Fatty Materials & Amphiphiles
• Surfactants & Solubilizers
• Proteins, Amino Acids & Other Organics
• Others
• Inorganic Chemicals
  • Salts & Buffers
  • Oxides & Hydroxides
  • Silicates, Aluminosilicates & Clays
  • Carbonates & Sulfates
  • Metal-based Specialty Excipients
  • Others

By Formulation * Oral Solid Dosage (OSD)

• Immediate-release tablets (IR)
• Modified-release tablets (ER/CR/SR)
• Capsules (hard gelatin; HPMC)
• ODT / dispersible tablets
• Others (OSD)
• Oral Liquids
  • Solutions/syrups
  • Suspensions
  • Emulsions
  • Oral drops
  • Others
• Parenteral
  • Small-volume parenterals (SVP)
  • Large-volume parenterals (LVP)
  • Lyophilized injectables
  • Depot/long-acting injectables
  • Others
• Topical & Transdermal
  • Creams
  • Ointments
  • Gels
  • Lotions
  • Others (Topical & transdermal)
• Pulmonary & Nasal
  • Dry powder inhalers (DPI)
  • Metered dose inhalers (MDI)
  • Nebulized solutions
  • Nasal sprays
  • Others
• Ophthalmic & Otic
  • Ophthalmic solutions
  • Ophthalmic suspensions
  • Ophthalmic ointments
  • Ophthalmic gels / in-situ gels
  • Others
• Rectal / Vaginal
  • Suppositories/pessaries
  • Rectal creams/ointments/gels
  • Vaginal creams/ointments/gels
  • Vaginal tablets
  • Others
• Others

By Functionality * Primary processing & performance roles

• Stability & protection roles
• Patient experience & adherence roles
• Device-compatibility roles
• Others

By Functionality Application * Stabilizers

• Taste masking
• Modified-release
• Solubility & bioavailability enhancement
• Immediate-release & content uniformity enablement
• Injectability & parenteral compatibility
• Preservation & microbial control
• Other functionality applications

By Source * Plant-derived (botanical)

• Animal-derived
• Mineral-derived
• Synthetic / petrochemical-derived
• Others

By End User * Pharmaceutical & Biopharmaceutical Companies

• CMOs / CDMOs
• Research & Academic Institutes
• Others

By Region * North America (By Type, Formulation, Functionality, Functionality Application, Source, End User, and Country)

• U.S.
• Canada
• Europe (By Type, Formulation, Functionality, Functionality Application, Source, End User, and Country/Sub-region)
  • Germany
  • U.K.
  • France
  • Spain
  • Italy
  • Scandinavia
  • Rest of Europe
• Asia Pacific (By Type, Formulation, Functionality, Functionality Application, Source, End User, and Country/Sub-region)
  • China
  • Japan
  • India
  • Australia
  • Southeast Asia
  • Rest of Asia Pacific
• Latin America (By Type, Formulation, Functionality, Functionality Application, Source, End User, and Country/Sub-region)
  • Brazil
  • Mexico
  • Rest of Latin America
• Middle East & Africa (By Type, Formulation, Functionality, Functionality Application, Source, End User, and Country/Sub-region)
  • GCC
  • South Africa
  • Rest of the Middle East & Africa

Table of Content

1. Introduction

• 1.1. Research Scope
• 1.2. Market Segmentation
• 1.3. Research Methodology
• 1.4. Definitions and Assumptions

2. Executive Summary

3. Market Dynamics

• 3.1. Market Drivers
• 3.2. Market Restraints
• 3.3. Market Opportunities
• 3.4. Market Trends

4. Key Insights

• 4.1. New Type Launches, By Key Players
• 4.2. Key Industry Developments (Mergers, Acquisitions, Partnerships, Launches, etc.)
• 4.3. Regulatory Scenario, By Key Countries/Regions
• 4.4. Overview: Advancements in Pharmaceutical Excipients

5. Global Pharmaceutical Excipients Market Analysis, Insights and Forecast, 2021-2034

• 5.1. Market Analysis, Insights and Forecast - By Type
  • 5.1.1. Organic Chemicals
    • 5.1.1.1. Carbohydrates & Derivatives
    • 5.1.1.2. Polymers
    • 5.1.1.3. Lipids, Fatty Materials & Amphiphiles
    • 5.1.1.4. Surfactants & Solubilizers
    • 5.1.1.5. Proteins, Amino Acids & Other Organics
    • 5.1.1.6. Others
  • 5.1.2. Inorganic Chemicals
    • 5.1.2.1. Salts & Buffers
    • 5.1.2.2. Oxides & Hydroxides
    • 5.1.2.3. Silicates, Aluminosilicates & Clays
    • 5.1.2.4. Carbonates & Sulfates
    • 5.1.2.5. Metal-based Specialty Excipients
    • 5.1.2.6. Others
• 5.2. Market Analysis, Insights and Forecast - By Formulation
  • 5.2.1. Oral Solid Dosage (OSD)
    • 5.2.1.1. Immediate-release tablets (IR)
    • 5.2.1.2. Modified-release tablets (ER/CR/SR)
    • 5.2.1.3. Capsules (hard gelatin; HPMC)
    • 5.2.1.4. ODT / dispersible tablets
    • 5.2.1.5. Others (OSD)
  • 5.2.2. Oral Liquids
    • 5.2.2.1. Solutions / syrups
    • 5.2.2.2. Suspensions
    • 5.2.2.3. Emulsions
    • 5.2.2.4. Oral drops
    • 5.2.2.5. Others (Oral liquids)
  • 5.2.3. Parenteral
    • 5.2.3.1. Small-volume parenterals (SVP)
    • 5.2.3.2. Large-volume parenterals (LVP)
    • 5.2.3.3. Lyophilized injectables
    • 5.2.3.4. Depot/long-acting injectables
    • 5.2.3.5. Others (Parenteral)
  • 5.2.4. Topical & Transdermal
    • 5.2.4.1. Creams
    • 5.2.4.2. Ointments
    • 5.2.4.3. Gels
    • 5.2.4.4. Lotions
    • 5.2.4.5. Others (Topical & transdermal)
  • 5.2.5. Pulmonary & Nasal
    • 5.2.5.1. Dry powder inhalers (DPI)
    • 5.2.5.2. Metered dose inhalers (MDI)
    • 5.2.5.3. Nebulized solutions
    • 5.2.5.4. Nasal sprays (solution; suspension)
    • 5.2.5.5. Others (Pulmonary & nasal)
  • 5.2.6. Ophthalmic & Otic
    • 5.2.6.1. Ophthalmic solutions
    • 5.2.6.2. Ophthalmic suspensions
    • 5.2.6.3. Ophthalmic ointments
    • 5.2.6.4. Ophthalmic gels / in-situ gels
    • 5.2.6.5. Others (Ophthalmic & otic)
  • 5.2.7. Rectal / Vaginal
    • 5.2.7.1. Suppositories / pessaries
    • 5.2.7.2. Rectal creams/ointments/gels
    • 5.2.7.3. Vaginal creams/ointments/gels
    • 5.2.7.4. Vaginal tablets
    • 5.2.7.5. Others (Rectal/vaginal)
  • 5.2.8. Others
• 5.3. Market Analysis, Insights and Forecast - By Functionality
  • 5.3.1. Primary processing & performance roles
  • 5.3.2. Stability & protection roles
  • 5.3.3. Patient experience & adherence roles
  • 5.3.4. Device-compatibility roles
  • 5.3.5. Others
• 5.4. Market Analysis, Insights and Forecast - By Functionality Application
  • 5.4.1. Stabilizers
  • 5.4.2. Taste masking
  • 5.4.3. Modified-release
  • 5.4.4. Solubility & bioavailability enhancement
  • 5.4.5. Immediate-release & content uniformity enablement
  • 5.4.6. Injectability & parenteral compatibility
  • 5.4.7. Preservation & microbial control
  • 5.4.8. Other functionality applications
• 5.5. Market Analysis, Insights and Forecast - By Source
  • 5.5.1. Plant-derived (botanical)
  • 5.5.2. Animal-derived
  • 5.5.3. Mineral-derived
  • 5.5.4. Synthetic / petrochemical-derived
  • 5.5.5. Others
• 5.6. Market Analysis, Insights and Forecast - By End User
  • 5.6.1. Pharmaceutical & Biopharmaceutical Companies
  • 5.6.2. CMOs / CDMOs
  • 5.6.3. Research & Academic Institutes
  • 5.6.4. Others
• 5.7. Market Analysis, Insights and Forecast - Region
  • 5.7.1. North America
  • 5.7.2. Europe
  • 5.7.3. Asia Pacific
  • 5.7.4. Latin America
  • 5.7.5. Middle East & Africa

6. North America Pharmaceutical Excipients Market Analysis, Insights and Forecast, 2021-2034

• 6.1. Market Analysis, Insights and Forecast - By Type
  • 6.1.1. Organic Chemicals
    • 6.1.1.1. Carbohydrates & Derivatives
    • 6.1.1.2. Polymers
    • 6.1.1.3. Lipids, Fatty Materials & Amphiphiles
    • 6.1.1.4. Surfactants & Solubilizers
    • 6.1.1.5. Proteins, Amino Acids & Other Organics
    • 6.1.1.6. Others
  • 6.1.2. Inorganic Chemicals
    • 6.1.2.1. Salts & Buffers
    • 6.1.2.2. Oxides & Hydroxides
    • 6.1.2.3. Silicates, Aluminosilicates & Clays
    • 6.1.2.4. Carbonates & Sulfates
    • 6.1.2.5. Metal-based Specialty Excipients
    • 6.1.2.6. Others
• 6.2. Market Analysis, Insights and Forecast - By Formulation
  • 6.2.1. Oral Solid Dosage (OSD)
    • 6.2.1.1. Immediate-release tablets (IR)
    • 6.2.1.2. Modified-release tablets (ER/CR/SR)
    • 6.2.1.3. Capsules (hard gelatin; HPMC)
    • 6.2.1.4. ODT / dispersible tablets
    • 6.2.1.5. Others (OSD)
  • 6.2.2. Oral Liquids
    • 6.2.2.1. Solutions / syrups
    • 6.2.2.2. Suspensions
    • 6.2.2.3. Emulsions
    • 6.2.2.4. Oral drops
    • 6.2.2.5. Others (Oral liquids)
  • 6.2.3. Parenteral
    • 6.2.3.1. Small-volume parenterals (SVP)
    • 6.2.3.2. Large-volume parenterals (LVP)
    • 6.2.3.3. Lyophilized injectables
    • 6.2.3.4. Depot/long-acting injectables
    • 6.2.3.5. Others (Parenteral)
  • 6.2.4. Topical & Transdermal
    • 6.2.4.1. Creams
    • 6.2.4.2. Ointments
    • 6.2.4.3. Gels
    • 6.2.4.4. Lotions
    • 6.2.4.5. Others (Topical & transdermal)
  • 6.2.5. Pulmonary & Nasal
    • 6.2.5.1. Dry powder inhalers (DPI)
    • 6.2.5.2. Metered dose inhalers (MDI)
    • 6.2.5.3. Nebulized solutions
    • 6.2.5.4. Nasal sprays (solution; suspension)
    • 6.2.5.5. Others (Pulmonary & nasal)
  • 6.2.6. Ophthalmic & Otic
    • 6.2.6.1. Ophthalmic solutions
    • 6.2.6.2. Ophthalmic suspensions
    • 6.2.6.3. Ophthalmic ointments
    • 6.2.6.4. Ophthalmic gels / in-situ gels
    • 6.2.6.5. Others (Ophthalmic & otic)
  • 6.2.7. Rectal / Vaginal
    • 6.2.7.1. Suppositories / pessaries
    • 6.2.7.2. Rectal creams/ointments/gels
    • 6.2.7.3. Vaginal creams/ointments/gels
    • 6.2.7.4. Vaginal tablets
    • 6.2.7.5. Others (Rectal/vaginal)
  • 6.2.8. Others
• 6.3. Market Analysis, Insights and Forecast - By Functionality
  • 6.3.1. Primary processing & performance roles
  • 6.3.2. Stability & protection roles
  • 6.3.3. Patient experience & adherence roles
  • 6.3.4. Device-compatibility roles
  • 6.3.5. Others
• 6.4. Market Analysis, Insights and Forecast - By Functionality Application
  • 6.4.1. Stabilizers
  • 6.4.2. Taste masking
  • 6.4.3. Modified-release
  • 6.4.4. Solubility & bioavailability enhancement
  • 6.4.5. Immediate-release & content uniformity enablement
  • 6.4.6. Injectability & parenteral compatibility
  • 6.4.7. Preservation & microbial control
  • 6.4.8. Other functionality applications
• 6.5. Market Analysis, Insights and Forecast - By Source
  • 6.5.1. Plant-derived (botanical)
  • 6.5.2. Animal-derived
  • 6.5.3. Mineral-derived
  • 6.5.4. Synthetic / petrochemical-derived
  • 6.5.5. Others
• 6.6. Market Analysis, Insights and Forecast - By End User
  • 6.6.1. Pharmaceutical & Biopharmaceutical Companies
  • 6.6.2. CMOs / CDMOs
  • 6.6.3. Research & Academic Institutes
  • 6.6.4. Others
• 6.7. Market Analysis, Insights and Forecast - By Country
  • 6.7.1. U.S.
  • 6.7.2. Canada

7. Europe Pharmaceutical Excipients Market Analysis, Insights and Forecast, 2021-2034

• 7.1. Market Analysis, Insights and Forecast - By Type
  • 7.1.1. Organic Chemicals
    • 7.1.1.1. Carbohydrates & Derivatives
    • 7.1.1.2. Polymers
    • 7.1.1.3. Lipids, Fatty Materials & Amphiphiles
    • 7.1.1.4. Surfactants & Solubilizers
    • 7.1.1.5. Proteins, Amino Acids & Other Organics
    • 7.1.1.6. Others
  • 7.1.2. Inorganic Chemicals
    • 7.1.2.1. Salts & Buffers
    • 7.1.2.2. Oxides & Hydroxides
    • 7.1.2.3. Silicates, Aluminosilicates & Clays
    • 7.1.2.4. Carbonates & Sulfates
    • 7.1.2.5. Metal-based Specialty Excipients
    • 7.1.2.6. Others
• 7.2. Market Analysis, Insights and Forecast - By Formulation
  • 7.2.1. Oral Solid Dosage (OSD)
    • 7.2.1.1. Immediate-release tablets (IR)
    • 7.2.1.2. Modified-release tablets (ER/CR/SR)
    • 7.2.1.3. Capsules (hard gelatin, HPMC)
    • 7.2.1.4. ODT / dispersible tablets
    • 7.2.1.5. Others (OSD)
  • 7.2.2. Oral Liquids
    • 7.2.2.1. Solutions / syrups
    • 7.2.2.2. Suspensions
    • 7.2.2.3. Emulsions
    • 7.2.2.4. Oral drops
    • 7.2.2.5. Others (Oral liquids)
  • 7.2.3. Parenteral
    • 7.2.3.1. Small-volume parenterals (SVP)
    • 7.2.3.2. Large-volume parenterals (LVP)
    • 7.2.3.3. Lyophilized injectables
    • 7.2.3.4. Depot/long-acting injectables
    • 7.2.3.5. Others (Parenteral)
  • 7.2.4. Topical & Transdermal
    • 7.2.4.1. Creams
    • 7.2.4.2. Ointments
    • 7.2.4.3. Gels
    • 7.2.4.4. Lotions
    • 7.2.4.5. Others (Topical & transdermal)
  • 7.2.5. Pulmonary & Nasal
    • 7.2.5.1. Dry powder inhalers (DPI)
    • 7.2.5.2. Metered dose inhalers (MDI)
    • 7.2.5.3. Nebulized solutions
    • 7.2.5.4. Nasal sprays (solution; suspension)
    • 7.2.5.5. Others (Pulmonary & nasal)
  • 7.2.6. Ophthalmic & Otic
    • 7.2.6.1. Ophthalmic solutions
    • 7.2.6.2. Ophthalmic suspensions
    • 7.2.6.3. Ophthalmic ointments
    • 7.2.6.4. Ophthalmic gels / in-situ gels
    • 7.2.6.5. Others (Ophthalmic & otic)
  • 7.2.7. Rectal / Vaginal
    • 7.2.7.1. Suppositories / pessaries
    • 7.2.7.2. Rectal creams/ointments/gels
    • 7.2.7.3. Vaginal creams/ointments/gels
    • 7.2.7.4. Vaginal tablets
    • 7.2.7.5. Others (Rectal/vaginal)
  • 7.2.8. Others
• 7.3. Market Analysis, Insights and Forecast - By Functionality
  • 7.3.1. Primary processing & performance roles
  • 7.3.2. Stability & protection roles
  • 7.3.3. Patient experience & adherence roles
  • 7.3.4. Device-compatibility roles
  • 7.3.5. Others
• 7.4. Market Analysis, Insights and Forecast - By Functionality Application
  • 7.4.1. Stabilizers
  • 7.4.2. Taste masking
  • 7.4.3. Modified-release
  • 7.4.4. Solubility & bioavailability enhancement
  • 7.4.5. Immediate-release & content uniformity enablement
  • 7.4.6. Injectability & parenteral compatibility
  • 7.4.7. Preservation & microbial control
  • 7.4.8. Other functionality applications
• 7.5. Market Analysis, Insights and Forecast - By Source
  • 7.5.1. Plant-derived (botanical)
  • 7.5.2. Animal-derived
  • 7.5.3. Mineral-derived
  • 7.5.4. Synthetic / petrochemical-derived
  • 7.5.5. Others
• 7.6. Market Analysis, Insights and Forecast - By End User
  • 7.6.1. Pharmaceutical & Biopharmaceutical Companies
  • 7.6.2. CMOs / CDMOs
  • 7.6.3. Research & Academic Institutes
  • 7.6.4. Others
• 7.7. Market Analysis, Insights and Forecast - By Country/ Sub-Region
  • 7.7.1. U.K.
  • 7.7.2. Germany
  • 7.7.3. France
  • 7.7.4. Italy
  • 7.7.5. Spain
  • 7.7.6. Scandinavia
  • 7.7.7. Rest of Europe

8. Asia Pacific Pharmaceutical Excipients Market Analysis, Insights and Forecast, 2021-2034

• 8.1. Market Analysis, Insights and Forecast - By Type
  • 8.1.1. Organic Chemicals
    • 8.1.1.1. Carbohydrates & Derivatives
    • 8.1.1.2. Polymers
    • 8.1.1.3. Lipids, Fatty Materials & Amphiphiles
    • 8.1.1.4. Surfactants & Solubilizers
    • 8.1.1.5. Proteins, Amino Acids & Other Organics
    • 8.1.1.6. Others
  • 8.1.2. Inorganic Chemicals
    • 8.1.2.1. Salts & Buffers
    • 8.1.2.2. Oxides & Hydroxides
    • 8.1.2.3. Silicates, Aluminosilicates & Clays
    • 8.1.2.4. Carbonates & Sulfates
    • 8.1.2.5. Metal-based Specialty Excipients
    • 8.1.2.6. Others
• 8.2. Market Analysis, Insights and Forecast - By Formulation
  • 8.2.1. Oral Solid Dosage (OSD)
    • 8.2.1.1. Immediate-release tablets (IR)
    • 8.2.1.2. Modified-release tablets (ER/CR/SR)
    • 8.2.1.3. Capsules (hard gelatin; HPMC)
    • 8.2.1.4. ODT / dispersible tablets
    • 8.2.1.5. Others (OSD)
  • 8.2.2. Oral Liquids
    • 8.2.2.1. Solutions / syrups
    • 8.2.2.2. Suspensions
    • 8.2.2.3. Emulsions
    • 8.2.2.4. Oral drops
    • 8.2.2.5. Others (Oral liquids)
  • 8.2.3. Parenteral
    • 8.2.3.1. Small-volume parenterals (SVP)
    • 8.2.3.2. Large-volume parenterals (LVP)
    • 8.2.3.3. Lyophilized injectables
    • 8.2.3.4. Depot/long-acting injectables
    • 8.2.3.5. Others (Parenteral)
  • 8.2.4. Topical & Transdermal
    • 8.2.4.1. Creams
    • 8.2.4.2. Ointments
    • 8.2.4.3. Gels
    • 8.2.4.4. Lotions
    • 8.2.4.5. Others (Topical & transdermal)
  • 8.2.5. Pulmonary & Nasal
    • 8.2.5.1. Dry powder inhalers (DPI)
    • 8.2.5.2. Metered dose inhalers (MDI)
    • 8.2.5.3. Nebulized solutions
    • 8.2.5.4. Nasal sprays (solution; suspension)
    • 8.2.5.5. Others (Pulmonary & nasal)
  • 8.2.6. Ophthalmic & Otic
    • 8.2.6.1. Ophthalmic solutions
    • 8.2.6.2. Ophthalmic suspensions
    • 8.2.6.3. Ophthalmic ointments
    • 8.2.6.4. Ophthalmic gels / in-situ gels
    • 8.2.6.5. Others (Ophthalmic & otic)
  • 8.2.7. Rectal / Vaginal
    • 8.2.7.1. Suppositories / pessaries
    • 8.2.7.2. Rectal creams/ointments/gels
    • 8.2.7.3. Vaginal creams/ointments/gels
    • 8.2.7.4. Vaginal tablets
    • 8.2.7.5. Others (Rectal/vaginal)
  • 8.2.8. Others
• 8.3. Market Analysis, Insights and Forecast - By Functionality
  • 8.3.1. Primary processing & performance roles
  • 8.3.2. Stability & protection roles
  • 8.3.3. Patient experience & adherence roles
  • 8.3.4. Device-compatibility roles
  • 8.3.5. Others
• 8.4. Market Analysis, Insights and Forecast - By Functionality Application
  • 8.4.1. Stabilizers
  • 8.4.2. Taste masking
  • 8.4.3. Modified-release
  • 8.4.4. Solubility & bioavailability enhancement
  • 8.4.5. Immediate-release & content uniformity enablement
  • 8.4.6. Injectability & parenteral compatibility
  • 8.4.7. Preservation & microbial control
  • 8.4.8. Other functionality applications
• 8.5. Market Analysis, Insights and Forecast - By Source
  • 8.5.1. Plant-derived (botanical)
  • 8.5.2. Animal-derived
  • 8.5.3. Mineral-derived
  • 8.5.4. Synthetic / petrochemical-derived
  • 8.5.5. Others
• 8.6. Market Analysis, Insights and Forecast - By End User
  • 8.6.1. Pharmaceutical & Biopharmaceutical Companies
  • 8.6.2. CMOs / CDMOs
  • 8.6.3. Research & Academic Institutes
  • 8.6.4. Others
• 8.7. Market Analysis, Insights and Forecast - By Country/ Sub-Region
  • 8.7.1. China
  • 8.7.2. Japan
  • 8.7.3. India
  • 8.7.4. Southeast Asia
  • 8.7.5. Australia
  • 8.7.6. Rest of Asia Pacific

9. Latin America Pharmaceutical Excipients Market Analysis, Insights and Forecast, 2021-2034

• 9.1. Market Analysis, Insights and Forecast - By Type
  • 9.1.1. Organic Chemicals
    • 9.1.1.1. Carbohydrates & Derivatives
    • 9.1.1.2. Polymers
    • 9.1.1.3. Lipids, Fatty Materials & Amphiphiles
    • 9.1.1.4. Surfactants & Solubilizers
    • 9.1.1.5. Proteins, Amino Acids & Other Organics
    • 9.1.1.6. Others
  • 9.1.2. Inorganic Chemicals
    • 9.1.2.1. Salts & Buffers
    • 9.1.2.2. Oxides & Hydroxides
    • 9.1.2.3. Silicates, Aluminosilicates & Clays
    • 9.1.2.4. Carbonates & Sulfates
    • 9.1.2.5. Metal-based Specialty Excipients
    • 9.1.2.6. Others
• 9.2. Market Analysis, Insights and Forecast - By Formulation
  • 9.2.1. Oral Solid Dosage (OSD)
    • 9.2.1.1. Immediate-release tablets (IR)
    • 9.2.1.2. Modified-release tablets (ER/CR/SR)
    • 9.2.1.3. Capsules (hard gelatin; HPMC)
    • 9.2.1.4. ODT / dispersible tablets
    • 9.2.1.5. Others (OSD)
  • 9.2.2. Oral Liquids
    • 9.2.2.1. Solutions / syrups
    • 9.2.2.2. Suspensions
    • 9.2.2.3. Emulsions
    • 9.2.2.4. Oral drops
    • 9.2.2.5. Others (Oral liquids)
  • 9.2.3. Parenteral
    • 9.2.3.1. Small-volume parenterals (SVP)
    • 9.2.3.2. Large-volume parenterals (LVP)
    • 9.2.3.3. Lyophilized injectables
    • 9.2.3.4. Depot/long-acting injectables
    • 9.2.3.5. Others (Parenteral)
  • 9.2.4. Topical & Transdermal
    • 9.2.4.1. Creams
    • 9.2.4.2. Ointments
    • 9.2.4.3. Gels
    • 9.2.4.4. Lotions
    • 9.2.4.5. Others (Topical & transdermal)
  • 9.2.5. Pulmonary & Nasal
    • 9.2.5.1. Dry powder inhalers (DPI)
    • 9.2.5.2. Metered dose inhalers (MDI)
    • 9.2.5.3. Nebulized solutions
    • 9.2.5.4. Nasal sprays (solution; suspension)
    • 9.2.5.5. Others (Pulmonary & nasal)
  • 9.2.6. Ophthalmic & Otic
    • 9.2.6.1. Ophthalmic solutions
    • 9.2.6.2. Ophthalmic suspensions
    • 9.2.6.3. Ophthalmic ointments
    • 9.2.6.4. Ophthalmic gels / in-situ gels
    • 9.2.6.5. Others (Ophthalmic & otic)
  • 9.2.7. Rectal / Vaginal
    • 9.2.7.1. Suppositories / pessaries
    • 9.2.7.2. Rectal creams/ointments/gels
    • 9.2.7.3. Vaginal creams/ointments/gels
    • 9.2.7.4. Vaginal tablets
    • 9.2.7.5. Others (Rectal/vaginal)
  • 9.2.8. Others
• 9.3. Market Analysis, Insights and Forecast - By Functionality
  • 9.3.1. Primary processing & performance roles
  • 9.3.2. Stability & protection roles
  • 9.3.3. Patient experience & adherence roles
  • 9.3.4. Device-compatibility roles
  • 9.3.5. Others
• 9.4. Market Analysis, Insights and Forecast - By Functionality Application
  • 9.4.1. Stabilizers
  • 9.4.2. Taste masking
  • 9.4.3. Modified-release
  • 9.4.4. Solubility & bioavailability enhancement
  • 9.4.5. Immediate-release & content uniformity enablement
  • 9.4.6. Injectability & parenteral compatibility
  • 9.4.7. Preservation & microbial control
  • 9.4.8. Other functionality applications
• 9.5. Market Analysis, Insights and Forecast - By Source
  • 9.5.1. Plant-derived (botanical)
  • 9.5.2. Animal-derived
  • 9.5.3. Mineral-derived
  • 9.5.4. Synthetic / petrochemical-derived
  • 9.5.5. Others
• 9.6. Market Analysis, Insights and Forecast - By End User
  • 9.6.1. Pharmaceutical & Biopharmaceutical Companies
  • 9.6.2. CMOs / CDMOs
  • 9.6.3. Research & Academic Institutes
  • 9.6.4. Others
• 9.7. Market Analysis, Insights and Forecast - By Country/ Sub-Region
  • 9.7.1. Brazil
  • 9.7.2. Mexico
  • 9.7.3. Rest of Latin America

10. Middle East & Africa Pharmaceutical Excipients Market Analysis, Insights and Forecast, 2021-2034

• 10.1. Market Analysis, Insights and Forecast - By Type
  • 10.1.1. Organic Chemicals
    • 10.1.1.1. Carbohydrates & Derivatives
    • 10.1.1.2. Polymers
    • 10.1.1.3. Lipids, Fatty Materials & Amphiphiles
    • 10.1.1.4. Surfactants & Solubilizers
    • 10.1.1.5. Proteins, Amino Acids & Other Organics
    • 10.1.1.6. Others
  • 10.1.2. Inorganic Chemicals
    • 10.1.2.1. Salts & Buffers
    • 10.1.2.2. Oxides & Hydroxides
    • 10.1.2.3. Silicates, Aluminosilicates & Clays
    • 10.1.2.4. Carbonates & Sulfates
    • 10.1.2.5. Metal-based Specialty Excipients
    • 10.1.2.6. Others
• 10.2. Market Analysis, Insights and Forecast - By Formulation
  • 10.2.1. Oral Solid Dosage (OSD)
    • 10.2.1.1. Immediate-release tablets (IR)
    • 10.2.1.2. Modified-release tablets (ER/CR/SR)
    • 10.2.1.3. Capsules (hard gelatin; HPMC)
    • 10.2.1.4. ODT / dispersible tablets
    • 10.2.1.5. Others (OSD)
  • 10.2.2. Oral Liquids
    • 10.2.2.1. Solutions / syrups
    • 10.2.2.2. Suspensions
    • 10.2.2.3. Emulsions
    • 10.2.2.4. Oral drops
    • 10.2.2.5. Others (Oral liquids)
  • 10.2.3. Parenteral
    • 10.2.3.1. Small-volume parenterals (SVP)
    • 10.2.3.2. Large-volume parenterals (LVP)
    • 10.2.3.3. Lyophilized injectables
    • 10.2.3.4. Depot/long-acting injectables
    • 10.2.3.5. Others (Parenteral)
  • 10.2.4. Topical & Transdermal
    • 10.2.4.1. Creams
    • 10.2.4.2. Ointments
    • 10.2.4.3. Gels
    • 10.2.4.4. Lotions
    • 10.2.4.5. Others (Topical & transdermal)
  • 10.2.5. Pulmonary & Nasal
    • 10.2.5.1. Dry powder inhalers (DPI)
    • 10.2.5.2. Metered dose inhalers (MDI)
    • 10.2.5.3. Nebulized solutions
    • 10.2.5.4. Nasal sprays (solution; suspension)
    • 10.2.5.5. Others (Pulmonary & nasal)
  • 10.2.6. Ophthalmic & Otic
    • 10.2.6.1. Ophthalmic solutions
    • 10.2.6.2. Ophthalmic suspensions
    • 10.2.6.3. Ophthalmic ointments
    • 10.2.6.4. Ophthalmic gels / in-situ gels
    • 10.2.6.5. Others (Ophthalmic & otic)
  • 10.2.7. Rectal / Vaginal
    • 10.2.7.1. Suppositories / pessaries
    • 10.2.7.2. Rectal creams/ointments/gels
    • 10.2.7.3. Vaginal creams/ointments/gels
    • 10.2.7.4. Vaginal tablets
    • 10.2.7.5. Others (Rectal/vaginal)
  • 10.2.8. Others
• 10.3. Market Analysis, Insights and Forecast - By Functionality
  • 10.3.1. Primary processing & performance roles
  • 10.3.2. Stability & protection roles
  • 10.3.3. Patient experience & adherence roles
  • 10.3.4. Device-compatibility roles
  • 10.3.5. Others
• 10.4. Market Analysis, Insights and Forecast - By Functionality Application
  • 10.4.1. Stabilizers
  • 10.4.2. Taste masking
  • 10.4.3. Modified-release
  • 10.4.4. Solubility & bioavailability enhancement
  • 10.4.5. Immediate-release & content uniformity enablement
  • 10.4.6. Injectability & parenteral compatibility
  • 10.4.7. Preservation & microbial control
  • 10.4.8. Other functionality applications
• 10.5. Market Analysis, Insights and Forecast - By Source
  • 10.5.1. Plant-derived (botanical)
  • 10.5.2. Animal-derived
  • 10.5.3. Mineral-derived
  • 10.5.4. Synthetic / petrochemical-derived
  • 10.5.5. Others
• 10.6. Market Analysis, Insights and Forecast - By End User
  • 10.6.1. Pharmaceutical & Biopharmaceutical Companies
  • 10.6.2. CMOs / CDMOs
  • 10.6.3. Research & Academic Institutes
  • 10.6.4. Others
• 10.7. Market Analysis, Insights and Forecast - By Country/ Sub-Region
  • 10.7.1. GCC
  • 10.7.2. South Africa
  • 10.7.3. Rest of Middle East & Africa

11. Competitive Analysis

• 11.1. Global Market Share Analysis (2025)
• 11.2. Company Profiles
  • 11.2.1. Roquette Freres
  • 11.2.2. BASF Pharma Solutions
  • 11.2.3. Evonik Industries AG
  • 11.2.4. Ashland Inc.
  • 11.2.5. Croda Pharma
  • 11.2.6. MEGGLE Excipients
  • 11.2.7. SPI Pharma, Inc.
  • 11.2.8. JRS Pharma GmbH & Co. KG
  • 11.2.9. Shin-Etsu Chemical Co., Ltd.
  • 11.2.10. Colorcon Limited.